Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study

被引：0
|
作者：
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
机构：
[1] Ctr Diabet & Metab, Bad Heilbrunn, Germany
[2] Novo Nordisk Ltd, Crawley, England
[3] Inst Metab Dis & Nutr, Med Abt Stoffwechselerkrankungen & Nephrol, Vienna, Austria
[4] Triemli City Hosp, Dept Endocrinol & Diabet, Zurich, Switzerland
[5] Novo Nordisk Pharma GmbH, Dept Diabet, Mainz, Germany
[6] Univ Tubingen, Med Klin 4, Tubingen, Germany
来源：
DIABETIC MEDICINE | 2007年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：75 / 75
页数：1
相关论文
共 50 条
  • [1] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A460 - A461
  • [2] The PREFER study: Dosing recommendations for biphasic insulin aspart 30, insulin detemir and insulin aspart using treat-to-target titration
    Gallwitz, B.
    Prager, R.
    Kaiser, M.
    Binz, K.
    Liebl, A.
    DIABETOLOGIA, 2006, 49 : 611 - 612
  • [3] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
    Liebl, Andreas
    Prager, Rudolf
    Kaiser, Marcel
    Binz, Katharina
    Gallwitz, Baptist
    DIABETES, 2006, 55 : A123 - A123
  • [4] The pharmacokinetic and pharmacodynamic properties of biphasic insulin aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin aspart 30 (BIAsp 30)
    Bott, S
    Tusek, C
    Heinemann, L
    Friberg, HH
    Heise, T
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2005, 113 (09) : 545 - 550
  • [5] Biphasic insulin aspart 30 (BIAsp 30) in clinical reality: Experience from a Dutch practice
    Ligthelm, Robert J.
    DIABETES, 2007, 56 : A540 - A540
  • [6] Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
    Fulcher, Gregory R.
    Christiansen, Jens Sandahl
    Bantwal, Ganapathi
    Polaszewska-Muszynska, Miroslawa
    Mersebach, Henriette
    Andersen, Thomas H.
    Niskanen, Leo K.
    DIABETES CARE, 2014, 37 (08) : 2084 - 2090
  • [7] Modeling of Pharmacokinetic Profiles of Insulin Aspart and Biphasic Insulin Aspart 30/70
    Kulesh, Victoria S.
    Drai, Roman, V
    Zinnatulina, Bella R.
    Makarenko, Igor E.
    Pilyus, Fedor G.
    Khokhlov, Alexander L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1086 - 1093
  • [8] Comparison of biphasic insulin aspart (BIAsp30) and insulin glargine (IGlarg) during isoglycaemic clamp studies in persons with type 2 diabetes
    Luzio, SD
    Peter, R
    Dunseath, GJ
    Pauvaday, V
    Owens, DR
    DIABETES, 2004, 53 : A136 - A136
  • [9] Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects
    Hassan, Mohammad Imtiaz
    Aamir, Azizul Hasan
    Miyan, Zahid
    Siddiqui, Laiq Ahmed
    Mahmood, Shahid
    Vohra, Ejaz Ahmed
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (10) : 1290 - 1294
  • [10] Insulin degludec/insulin aspart (IDegAsp) twice daily (BID) vs biphasic insulin aspart 30 (BIAsp 30) BID: a randomised trial in Chinese patients with type 2 diabetes
    Ma, J.
    Yang, W.
    Hong, T.
    Liu, M.
    Miao, H.
    Peng, Y.
    Wang, C.
    Xu, X.
    Yang, T.
    Liu, W.
    Nielsen, A. Moeller
    Pan, L.
    Weigang, Z.
    DIABETOLOGIA, 2018, 61 : S410 - S411
12345